Compare Schwab US Dividend Equity ETF (SCHD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Schwab US Dividend Equity ETFTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Schwab US Dividend Equity ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Schwab US Dividend Equity ETF trades at $34.23, while State Street SPDR S&P Biotech ETF trades at $159.85. Which is the better fit depends on your goals.

	SCHD	XBI
Sector	Broad Market / Factor	Broad Market / Factor
52-Week High	$35.21	$169.55
52-Week Low	$26.44	$93.43

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Schwab US Dividend Equity ETF

SCHD trades at $34.41, down 1.12% over the past day, with technical indicators showing a mixed but overall bullish bias. The ETF's recent dividend announcement for June 2026 highlights its income focus, while news coverage emphasizes its role in retirement portfolios and comparisons with peers like JEPI. Support and resistance levels are tightly clustered around $34-$35, indicating potential for near-term consolidation.

The outlook for SCHD remains favorable for dividend-focused investors, supported by strong inflows and media optimism, though risks include market volatility and competition from other income ETFs. Its low expense ratio and quality screening process continue to attract long-term holders seeking steady income and moderate growth.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SCHD

Schwab's international dividend ETF returned 28% in a year, yielding 3.7% with low fees.24/7 Wall Street · 15 hours agoBullish iShares Select Dividend ETF (DVY) rated 'hold' for average growth and weak quality despite solid dividend yield.Seeking Alpha · 21 hours agoNeutral Capital Group Dividend Value ETF rated 'hold' for balanced factors and strong returns since 2022 launch.Seeking Alpha · 1 day agoNeutral View details →

XBI

Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rallySeeking Alpha · 4 days agoBullish View details →

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.